GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

CNBX Pharmaceuticals CNBX · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

0.00%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

—

FY2016FY2025

Net income

−$313,976

FY2016FY2025

Free cash flow

−$171,305

FY2016FY2025

Shareholders' equity

−$2.5m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue—$130,074$410,165$29,958—$7,157$9,843$9,601$5,684$112,500
Research and development—$194,788$431,565$1.2m$1.8m$1.7m$1.5m$1.0m$246,943$177,607
Operating income−$271,691−$583,000−$931,000−$3.0m−$2.6m−$3.0m−$3.3m−$3.8m−$1.9m−$281,000
Net income−$313,976−$695,000−$3.7m−$3.7m−$3.2m−$7.5m$1.1m−$3.8m−$1.9m−$307,000
Diluted earnings per share-0.00-0.02-0.13-2.96-2.92-6.631.02-3.68-1.94-0.34

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$18,437$31,383$499,039$811,166$3.1m$2.2m$15.2m$3.2m$3.6m$23,716
Cash and short-term investments$15,111$26,416$129,696$117,515$1.4m$777,611$3.5m$1.4m$3.4m—
Total liabilities$2.5m$2.5m$2.5m$2.4m$1.3m$454,787$438,873$539,382$699,123$491,165
Debt$1.2m$1.3m$1.3m$1.8m$871,896—————
Shareholders' equity−$2.5m−$2.5m−$2.0m−$1.6m$1.8m$1.8m$14.7m$2.6m$2.9m−$467,449
Shares outstanding733m31m28m1m1m1m1m1m1m1m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−$171,305−$244,269−$112,521−$1.7m−$2.5m−$2.8m−$3.1m−$2.0m−$863,567−$120,103
Capital spending—−$1,196−$1−$1,656−$943−$75,748−$216,882−$942,394−$125,775−$125,775
Free cash flow−$171,305−$245,465−$112,522−$1.7m−$2.5m−$2.9m−$3.3m−$2.9m−$989,342−$245,878

Latest quarters

By quarter end

May 2026Feb 2026Nov 2025Aug 2025May 2025Feb 2025Nov 2024Aug 2024
Revenue———————−$17,570
Operating income−$162,763−$72,963−$64,000−$129,731−$40,380−$64,743−$36,837−$52,533
Net income−$154,165−$44,098−$113,719−$150,109−$59,727−$69,788−$34,352−$60,584
Diluted earnings per share-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00
Total assets$12,795$14,899$11,162$18,437$18,615$50,660$22,308$31,383
Cash and short-term investments$9,487$12,154$7,703—$13,648$45,675$17,339$26,416
Debt$120,000$75,000$1.2m—$1.3m$1.4m$1.3m$1.3m
Shareholders' equity−$2.7m−$2.5m−$2.6m−$2.5m−$2.5m−$2.6m−$2.5m−$2.5m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income-54.9%-38.3%-6.6%
Net income-56.1%-46.9%-5.3%

Valuation history

At each fiscal year end

FY2025FY2024FY2022FY2020FY2019FY2018FY2017FY2016
Price to earnings-0.0—————-0.0-0.1
Price to sales—0.00.01.20.51.27.60.1

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return-78%35%-97%-53%-70%152%-67%-52%69%3441%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 120-to-1 reverse split · 12 May 2022
  • 2-for-1 split · 30 Jun 2014

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.